What the research found

The text presents a clinical framework for evaluating cardiovascular risk, categorizing tests into three groups: those that visualize plaque directly (structural imaging), those that assess heart function under stress (functional testing), and blood markers that reflect underlying disease drivers.

The key distinction drawn is between what you have (plaque burden and type) and how well your heart works. Standard screening often misses the former. For instance, coronary calcium scoring—which detects only calcified plaque—fails to identify softer, lipid-rich plaque in roughly 40% of people who appear low-risk by that measure alone. Conversely, tests like echocardiography excel at evaluating valve health and ejection fraction but reveal little about plaque accumulation.

Among blood markers, apolipoprotein B emerges as the most direct link to plaque formation, though it often tracks so closely with LDL that measuring both may offer limited additional insight. Lipoprotein(a), determined largely by genetics, warrants screening at least once; emerging evidence suggests some medications and hormonal interventions may modulate it modestly. Triglycerides serve as a lifestyle barometer—improvement almost reliably reflects behavioural change—while inflammatory markers like high-sensitivity CRP require careful interpretation given their sensitivity to acute illness.

Why it matters for you

If you're tracking cardiovascular biomarkers on MyKine, you're likely measuring LDL, triglycerides, and possibly inflammation. These are useful signals, but they're incomplete. A normal lipid panel doesn't exclude silent plaque. The framework here suggests that if you have risk factors—family history, elevated Lp(a), metabolic dysfunction, or smoking—structural imaging (carotid ultrasound or CT angiography) may reveal disease that standard bloodwork misses. That information directly informs whether your current protocol—whether that's statin dosing, dietary intervention, or exercise intensity—is actually working against plaque, or merely managing biomarker numbers.

For those using TRT or other hormonal interventions, Lipoprotein(a) becomes especially relevant: it's a genetic anchor point that baseline screening can establish, and some evidence hints that estradiol levels may influence it. Similarly, fasting insulin and glucose tolerance tests (alongside A1c) give a more granular view of metabolic health than A1c alone, which can lag behind real-time changes in your diet or training load. If you're optimizing for longevity, these gaps between "normal" lab work and actual arterial status are worth investigating.

Stress testing and functional imaging (stress echo, treadmill tests) assess reserve capacity—how your cardiovascular system responds to demand. That's distinct from plaque burden and offers insight into training efficacy and true cardiorespiratory fitness, not just VO₂ max estimates.

Caveats

  • Observational and expert opinion — this is a clinician's framework, not a controlled trial. No effect sizes or outcome data are provided.
  • Imaging access varies — carotid ultrasound and CT angiography availability and cost depend heavily on jurisdiction and insurance; some tests mentioned are routinely denied coverage.
  • Single-vessel disease gap — even advanced carotid imaging can miss isolated blockages in the coronary arteries, which is why CT angiography is sometimes necessary despite higher cost.
  • Lp(a) interventions are nascent — the evidence for PCSK9 inhibitors and HRT modulating Lipoprotein(a) is described as "recent" and modest in effect, not established standard practice.
  • Biomarker interpretation context-dependent — CRP, triglycerides, and other markers require clinical context; acute infection, stress, or sleep debt can skew results independently of true cardiovascular risk.